Skip to main content
SpringerLink
Log in

HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors

  • Protocol
Gene Therapy of Cancer

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 35))

  • 656 Accesses

Abstract

Gliomas account for about 60% of all primary CNS tumors; two-thirds of all gliomas comprise the most malignant form, glioblastoma multiforme, or glioma grade IV. Although much progress has been achieved in the treatment of other solid tumors over the last few decades, the median survival of patients with glioblastoma remains at around 12 mo after standard treatment, which includes bulk resection and irradiation, as well as chemotherapy in some cases (1). Essentially, no patient can expect to survive 5 yr. New treatment modalities like immunotherapy have been applied so far with only limited success (2). With the improvement of methods for in vivo and ex vivo gene delivery, gene therapy became a new, promising approach to glioma therapy. Gliomas appear to be a particularly good target for a gene therapy approach using locally applied vectors, as the growth of gliomas is restricted to the brain. Clinical trials are under way using retrovirus and adenovirus vectors which carry the herpes simplex virus type-1 (HSV-1) thymidine kinase gene (HSV-tk). This gene encodes a prodrug-activating enzyme, which in infected cells converts the nontoxic prodrug, ganciclovir (GCV), to its cytotoxic phosphorylated form (3-5). There is an ever-increasing list of other prodrug-activation systems that showed efficacy in culture and in preclinical studies using rodent glioma models. These include, for example, cytosine deaminase converting 5-fluorocytosine to 5-fluoro-uracil (6), cytochrome P450-2B1 converting cyclophosphamide to phosphoramide mustard (7), deoxycytidine kinase phosphorylating cytosine arabinoside (8), and the Escherichia coli guanine phosphoribosyl transferase (gpt) metabolizing 6-thioxanthine and 6-thioguanine to toxic nucleoside analogs (9). Moreover, gene therapy approaches to brain tumors include the viral transfer of immune-enhancing cytokines, particularly granulocyte/macrophage colony-stimulating factor (10), or antisense to TGF-β to glioma cells (11) used for vaccination purposes. Other approaches use the transfer of genes that modulate angiogenesis (12,13) or are involved in apoptosis like p53 (14). All aforementioned gene-transfer methods use nonreplicative viral vectors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Damek, D. M. and Hochberg, F. H. (1997) Clinical aspects of brain tumor. Curr. Opin. Neurol. 10, 452–458.

    Article  PubMed  CAS  Google Scholar 

  2. Sampson J. H., Bigner, D. D., and Dranoff, G. (1998) Cytokine-based gene therapy of brain tumors, in Gene Transfer and Therapy of Neurological Disorders (Chiocca, E. A. and Breakefield, X. O., eds.). Humana, Totowa, NJ, pp. 227–290.

    Google Scholar 

  3. Eck, S. L., Alavi, J. B., Alavi, A., Davis, A., Hackney, D., Judy, K., et al. (1996) Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum. Gene. Ther. 7, 1465–1482.

    Article  PubMed  CAS  Google Scholar 

  4. Berger, M. S., Prados, M. D., Van Gilder, J. C., Warnick, R. E., McDermott, M. W., Marcus, S. G., and Kapcala, L. P. (1997) Phase II trial of GLI 328 HSV-TK gene therapy in recurrent glioblastoma. Cancer Gene Ther. 4, S42.

    Google Scholar 

  5. Ram, Z., Culver, C. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., et al. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 12, 1354–1361.

    Article  Google Scholar 

  6. Huber, B. E., Austin, E. A., Goode, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. (1993) In vivo antitumor activity of 5-gluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619–4626.

    PubMed  CAS  Google Scholar 

  7. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. U., Chang, T. K. H., and Hochberg, P., et al. (1994) Experimental tumor therapy in mice with the cyclo-phosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5, 969–978.

    Article  PubMed  CAS  Google Scholar 

  8. Manome, Y., Wen, P. Y., Dong, Y., Tanaka, T., Mitchell, B. S., Kufe, D. W., and Fine, H. A. (1996) Viral vector transduction of the human deoxyxytidine kinase cDNA sensitizes glioma cells to the cytocoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2, 567–573.

    Article  PubMed  CAS  Google Scholar 

  9. Tamiya, T., Ono, Y., Wei, M. X., Mroz, P., Moolten, F. L., and Chiocca, E. A. (1996) The Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 3, 155–162.

    PubMed  CAS  Google Scholar 

  10. Herrlinger, U., Kramm, C. M., Johnston, K. M., Louis, D. N., Finkelstein, D., Reznikoff, G., et al. (1997) Vaccination for experimental gliomas using GM-CSF transduced glioma cells. Cancer Gene Ther. 4, 345–352.

    PubMed  CAS  Google Scholar 

  11. Fahkrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., et al. (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense therapy. Proc. Natl. Acad. Sci. USA 93, 2909–2914.

    Article  Google Scholar 

  12. Millauer, B., Shawyer, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–578.

    Article  PubMed  CAS  Google Scholar 

  13. Saleh, M., Stacker, S. A., and Wilks, A. F. (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393–401.

    PubMed  CAS  Google Scholar 

  14. Gomez-Manzano, C., Fueyo, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonell, T. J., et al. (1996) Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56, 694–699.

    PubMed  CAS  Google Scholar 

  15. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–856.

    Article  PubMed  CAS  Google Scholar 

  16. Boviatsis, E. J., Park. J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., et al. (1994) Long-term survival of rats harbouring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an active thymidine kinase gene. Cancer Res. 54, 5745–5761.

    PubMed  CAS  Google Scholar 

  17. Chase, M., Chung, R. Y., and Chiocca, E. A. (1998) An oncolytic viral mutant that delivers the CVP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444–448.

    Article  PubMed  CAS  Google Scholar 

  18. Montgomery, R. I., Warner, M. S., Lum, B. J., and Spear, P. G. (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427–436.

    Article  PubMed  CAS  Google Scholar 

  19. Wu, N., Watkins, S. C., Schaffer, P. A., and DeLuca, N. A. (1996) Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70, 6358–6369.

    PubMed  CAS  Google Scholar 

  20. Goldstein, D. J. and Weller, S. (1988) Herpes simplex virus type 1-induced ribo-nucleotide reductase activity is indispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196–205.

    PubMed  CAS  Google Scholar 

  21. Kaplitt, M. G., Tjuvajev, J. G., Leib, D. A., Berk, J., Pettigrew, K. D., Posner, J. B., et al. (1994) Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-Oncol. 19, 137–147. 309

    Article  CAS  Google Scholar 

  22. Pyles, R. B. and Thompson, R. L. (1994) Evidence that Herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Virol. 68, 4963–4972.

    PubMed  CAS  Google Scholar 

  23. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990) Mapping of herpes simplex virus-1 neurovirulence to yj34.5, a gene nonessential for growth in culture. Science 250, 1262–1266.

    Article  PubMed  CAS  Google Scholar 

  24. Chou, J., Chen, J.-J., Gross, M., and Roizman, B. (1995) Association of a novel Mr 90,000 phosphoprotein with PKR kinase in cells exhibiting enhanced phos-phorylation of EIF-2alpha and premature shut-off of protein synthesis after infection with γ134.5- mutants of herpes simplex virus. Proc. Natl. Acad. Sci. USA 92, 10,516–10,520.

    Article  PubMed  CAS  Google Scholar 

  25. Pyles, R. B., Warnick, R. E., Chalk, C. L., Szanti, B. E., and Parysek, L. M. (1997) A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533–544.

    Article  PubMed  CAS  Google Scholar 

  26. Mineta, T., Rabkin, S. D., Yazaki, T., and Hunter, W. D. (1995) Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938–943.

    Article  PubMed  CAS  Google Scholar 

  27. Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A, Sena-Esteves, M., et al. (1997) Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057–2068.

    Article  PubMed  CAS  Google Scholar 

  28. Chou, J., Poon, A. P. W., Johnson, J., and Roizman, B. (1994) Differential response of human cells to deletions and stop codons in the γ134.5 gene of herpes simplex virus. J. Virol. 68, 8304–8311.

    PubMed  CAS  Google Scholar 

  29. Krisky, D., Marconi, P., Goins, W. F., Glorioso, J. C. (1997) Development of replication-defective herpes simplex virus vectors, in Methods in Molecular Medicine, Gene Therapy Protocols (Robbins, P., ed.), Humana, Totowa, NJ, pp. 79–102.

    Google Scholar 

  30. Boviatsis, E. J., Scharf, J. M., Chase, M., Harrington, K., Kowall, N. W., Breakefield, X. O., and Chiocca, E. A. (1994) Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323–331.

    PubMed  CAS  Google Scholar 

  31. Jacobs, A., Tjuvajev, J. G., Joshi, A., Joshi, R., Herrlinger, U., Avril, N., et al. Quantitative kinetics of HSV1-tk gene delivery by a recombinant HSV-1 virus vector in tumor cells: implications for imaging rHSV-1 mediated gene transfer in vivo. Submitted.

    Google Scholar 

  32. Herrlinger, U., Kramm, C. M., Aboody-Guterman, K. S., Silver, J. S., Johnston, J. M., Pechan, P., et al. (1998) Pre-existing Herpes simplex virus-1 (HSV-1) immunity decreases but does not abolish gene transfer by a HSV-1 mutant vector. Gene Ther. 5, 809–819.

    Article  PubMed  CAS  Google Scholar 

  33. Andreansky, S. S., He, B., Gillespie, G. Y., Soroceanu, L., Markert, J., Chou J., et al. (1996) The application of genetically engineered herpes simplex viruses to 310 the treatment of experimental brain tumors. Proc. Nat l. Acad. Sci. USA 93, 11,313–11,318.

    Article  CAS  Google Scholar 

  34. Andreansky, S., Soroceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., et al. (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57, 1502–1509.

    PubMed  CAS  Google Scholar 

  35. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., et al. (1995) Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92, 1411–1415.

    Article  PubMed  CAS  Google Scholar 

  36. Toda, T., Rabkin, S. D., and Martuza, R. L. (1997) Lack of ganciclovir-mediated antitumor effect when thymidine kinase is present in a replication-competent herpes simplex virus. Proc. Am. Assoc. Cancer Res. 38, 14.

    Google Scholar 

  37. Rainov, N. G., Zimmer, C., Chase, M., Kramm, C. M., Chiocca, E. A., Weissleder, R., and Breakefield, X. O. (1995) Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain tumors. Hum. Gene Ther. 6, 1543–1552.

    Article  PubMed  CAS  Google Scholar 

  38. Rainov, N. G., Dobberstein, K. U., Heidecke, V., Dorant, U., Chase, M., Kramm, C. M., et al. (1998) Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes-simplex virus vector. Cancer Gene Ther. 5, 158–162.

    PubMed  CAS  Google Scholar 

  39. Barnett, F. H., Ikeda, K., Rainov, N. G., Schuback, D. E., Elliott, P., Kramm, C., et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 6, 14–20.

    Google Scholar 

  40. Kramm, C. M., Rainov, N. G., Sena-Esteves, M., Barnett, F. H., Chase, M., Herrlinger, U., et al. (1996) Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum. Gene Ther. 7, 1989–1994.

    Article  PubMed  CAS  Google Scholar 

  41. Corey, L. and Spear, P. G. (1986) Infections with Herpes simplex viruses. N. Engl. J. Med. 314, 686–691.

    Article  PubMed  CAS  Google Scholar 

  42. Baringer, J. R. and Pisani, P. (1994) Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36, 823–829.

    Article  PubMed  CAS  Google Scholar 

  43. Wang, Q., Guo, J., and Jia, W. (1997) Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther. 4, 1300–1344.

    Article  PubMed  CAS  Google Scholar 

  44. Forrester, A., Farrell, H., Wilkinson, G., Kaye, J., Davis-Poynter, N., and Minson, T. (1992) Construction and properties of a mutant of herpes simplex virus type I with glycoprotein H coding sequences deleted. J. Virol. 66, 341.

    PubMed  CAS  Google Scholar 

  45. Dilloo, D., Rill, D., Entwisle, C., Boursnell, M., Zhong, W., Holden, W., et al. (1997) A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoetic cells. Blood 89, 119–127.

    PubMed  CAS  Google Scholar 

  46. Johnston, K. M., Jacoby, D., Pechan, P. A., Fraefel, C., Borghesani, P., Schuback, D., et al. (1997) HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 8, 359–370.

    Article  PubMed  CAS  Google Scholar 

  47. Wang, S. and Vos, J. (1996) A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type I for gene transfer into human cells in vitro and in vivo. J. Virol 70, 8422–8430.

    PubMed  CAS  Google Scholar 

  48. Ho, D. (1994) Amplicon-based herpes simplex vectors. Meth. Cell. Biol. 43, 191–210.

    Article  CAS  Google Scholar 

  49. Tung, C., Federoff, H. J., Brownlee, M., Karpoff, H., Weigel, T., Brennan, M. F., and Fong, Y. (1996) Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum. Gene Ther. 7, 2217–2224.

    Article  PubMed  CAS  Google Scholar 

  50. Miyatake, S., Martuza, R. L., and Rabkin, S. D. (1997) Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 4, 222–228.

    PubMed  CAS  Google Scholar 

  51. Pechan, P. A., Fotaki, M., Thompson, R. L., Dunn, R., Chase, M., Chiocca, E. A., and Breakefield, X. O. (1996) A novel’ piggyback’ packaging system for herpes simplex virus amplicon vectors. Hum. Gene Ther. 7, 2003–2013.

    Article  PubMed  CAS  Google Scholar 

  52. Pechan, P. A., Herrlinger, U., Aghi, M., Jacobs, A., Johnston, K., Dunn, R., and Breakefield, X. O. (1999) Enhanced therapeutic efficacy of combined HSV-1 recombinant and amplicon vectors for experimental glioma tumors. J. Gene Med. 1, 176–185.

    Article  PubMed  CAS  Google Scholar 

  53. Fraefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., et al. (1996) Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70, 7190–7197.

    PubMed  CAS  Google Scholar 

  54. Weizsaecker, M., Deen, D. F., Rosenblum, M. L., et al. (1981) The 9L rat brain tumor: description and application of an animal model. J. Neurol. 224, 183–192.

    Article  PubMed  CAS  Google Scholar 

  55. Jacobs, A., Herrlinger, U., Chiocca, E. A., and Breakefield, X. O. Rapid titration of replication-conditional HSV-1 vectors: implications for the comparison of infectious units between different viral vectors. Submitted.

    Google Scholar 

  56. Preston, V. G., Darling, A. J., and McDougal, I. M. (1988) The herpes simplx virus type 1 temperature-sensitive mutant ts1222 has a single base pair deletion in the small subunit of ribonucleotide reductase. Virology 167, 458–467.

    PubMed  CAS  Google Scholar 

  57. Tzeng, J., Barth, R. F., Grosz, C. G., and James, S. M. (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and non-immunogenic rat brain tumors. Cancer Res. 51, 2373–2378.

    PubMed  CAS  Google Scholar 

  58. Aghi, M., Kramm, C. M., Chou, T.-C., Breakefield, X. O., and Chiocca, E. A. (1998) Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-gluorocytosine/ cytosine desaminase gene therapies. J. Natl. Cancer Inst. 90, 370–380.

    Article  PubMed  CAS  Google Scholar 

  59. Rosenberg, W. S., Breakefield, X. O., DeAntonio, C., and Isacson, O. (1992) Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods. Mol. Brain Res. 16, 311–315.

    Article  PubMed  CAS  Google Scholar 

  60. Rhodes, J. M., Rasmussen, S. E., Burchardt, S., and Larsen, S. O. (1987) Modulation of beta-galactosidase activity in peritoneal macrophages from C57B1 mice after exposure to Propionibacterium acnes. Acta Pathol. Microbiol. Immunol. Scand. 95, 213–220. 312

    CAS  Google Scholar 

  61. Kruse, C. A., Roper, M. D., Kleinschmidt-DeMasters, B. K., Banuelos, S. J., Smiley, W. R., Robbins, J. M., and Burrows, F. J. (1996) Purified herpes simplex thymidine kinase Retrovector™ particles. I. In vitro characterization, in situ trasnduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther. 4, 118–128.

    Google Scholar 

  62. Roizman, B. and Batterson, W. (1985) Herpesviruses and their replication, in Virology (Fields, B. N., ed.), Raven, New York, pp. 497–526.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Universitätsklinik Tübingen, Tübingen, Germany

    Ulrich Herrlinger

  2. Molecular Neurogenetics Unit, Massachusetts General, Hospital East, Charlestown, MA

    Andreas Jacobs

  3. Molecular Neurogenetics Unit, Massachusetts General Hospital East, Charlestown, MA

    Manish Aghi, Deborah E. Schuback & Xandra O. Breakefield

Authors
  1. Ulrich Herrlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manish Aghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deborah E. Schuback
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xandra O. Breakefield
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Wolfgang Walther  & Ulrike Stein  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Herrlinger, U., Jacobs, A., Aghi, M., Schuback, D.E., Breakefield, X.O. (2000). HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Medicine™, vol 35. Humana Press. https://doi.org/10.1385/1-59259-086-1:287

Download citation

  • DOI: https://doi.org/10.1385/1-59259-086-1:287

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-714-4

  • Online ISBN: 978-1-59259-086-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation